The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
The Actions and Interactions of Sex Steroids and Growth Factors/Cytokines on the Skeleton
Open accessAbstract
The discoveries that sex steroid receptors for estrogen [estrogen receptor (ER)], androgen [androgen receptor (AR)], and progesterone [progesterone receptor (PR)] are present in the bone-forming osteoblasts (OB) and bone-resorbing osteoclasts (OCL), and that these cells are targets for sex steroid action, have generated much excitement in the field of bone biology. The subsequent discoveries that the sex steroids regulate the production of growth factors and cytokines in these OB and OCL cells and that these factors mediate much of the steroid action on the skeleton have added to the excitement and complexity of the system. Because of the required brevity of this minireview, we will discuss only selected aspects of this field using a limited number of references and review articles. For more information in this field, readers are referred to several recent books and chapters that review bone biology, bone diseases, and the role of sex steroids in bone biology and disease (1–8). As a brief background to this unique system, the skeletal maintenance involves a continuous remodeling at discrete sites termed bone-remodeling units (BRU). As outlined in Fig. 1, the multinucleated bone-resorbing OCLs first dissolve bone at these BRU sites, resulting in resorption cavities. While the mechanism(s)/signal(s) that initiates resorption at a given site is unknown, there appears to be a marked regulation of overall bone resorption via the regulation of the OCL differentiation and activity (5–8). These processes are discussed in more detail below. The bone-forming OBs are then recruited by unknown signals, to replace the previously resorbed bone. The identities of the primary factors that couple these processes of resorption to formation to maintain bone mass are also addressed later in this review and are still the subject of much debate. During periods of skeletal growth in children, the increase in bone formation largely involves bone modeling (accretion of bone at surfaces in the absence of bone resorption). The response to mechanical stresses also utilizes mostly modeling. During early adulthood (20–40 yr), bone resorption and formation are in balance and bone mass is maintained. The increased serum estrogen (E) level, which occurs at the onset of puberty in girls, is accompanied by an increase in growth velocity and, ultimately, in the closure of the epiphyseal growth plate and the cessation of linear growth (9). E is the primary hormone responsible for maintaining bone mass in adult women and may serve a similar role along with androgen, in adult men. Finally, during periods of bone loss, such as in postmenopause in women and aging in both genders, bone resorption outpaces bone formation and, in some cases, the bone loss is sufficient to cause osteoporosis. Schematic of the Steroid Actions and Interactions with Growth Factors/Cytokines in Bone Cells at Bone Resorption and Formation Site This model is self-explanatory. The solid arrows represent pathways with significant support in the literature. The broken lines represent potential pathways not currently well identified or characterized (4, 5, 6, 7, 8 ). Schematic of the Steroid Actions and Interactions with Growth Factors/Cytokines in Bone Cells at Bone Resorption and Formation Site This model is self-explanatory. The solid arrows represent pathways with significant support in the literature. The broken lines represent potential pathways not currently well identified or characterized (4, 5, 6, 7, 8 ). It is currently accepted that in postmenopausal females, a deficiency of E results in osteoporosis, whereas in aging males, the deficiency of E and androgens (A) may lead to bone loss (1–3). Ovariectomized (OVX) animals and postmenopausal women experience increased bone turnover, increased bone resorption, and an overall decrease in bone mass. On the other hand, E replacement therapy inhibits this bone loss by inhibiting bone turnover and bone resorption, which prevents the development of osteoporosis (1, 3). Although, the complete mechanisms of action of E in this protection against bone loss are still unclear, new studies are beginning to elucidate the molecular processes involved. The following review summarizes some of the important molecular events in the actions of sex steroids, primarily estrogens, which have been recently reported on the skeleton and bone cells, as well as the role that growth factors and cytokines play in this action. For more details, the readers are referred to several recent reviews that emphasize various aspects of steroid action on bone biology (4–8). That bone cells, especially OB cells, contain ER is fairly well established. Using sensitive techniques, such as immunofluorescence, semiquantitative RT-PCR, in situ hybridization, and in situ RT-PCR, both the ER mRNA and ER protein have been identified in periosteal cells, OBs, osteocytes, and OCLs, at levels less than the reproductive organs, but equivalent to those in liver (9–13). More
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Estrogen Resistance Caused by a Mutation in the Estrogen-Receptor Gene in a Man
Smith, E. P., Boyd, J., Frank, G. R., Takahashi, H., Cohen, R. M., Specker, B., Williams, T. C., Lubahn, D. B., & Korach, K. S. (1994) · New England Journal of Medicine · doi:10.1056/nejm199410203311604 · Cited by 2,471
Estrogen promotes apoptosis of murine osteoclasts mediated by TGF–β
Hughes, D. E., Dai, A., Tiffee, J. C., Li, H. H., Mundy, G. R., & Boyce, B. F. (1996) · Nature Medicine · doi:10.1038/nm1096-1132 · Cited by 813 · cited 3×
“The E induction of apoptosis may be further enhanced in vivo since TGF-b, whose production by OB is enhanced by E, was also shown to induce OCL apoptosis in these cultures (34).”
BackgroundHofbauer, L. C., Khosla, S., Dunstan, C. R., Lacey, D. L., Spelsberg, T. C., & Riggs, B. L. (1999) · Endocrinology · doi:10.1210/endo.140.9.7131 · Cited by 692 · cited 1×
“Interestingly, E treatment of human OB cells increased OPG mRNA steady state levels and OPG protein secretion, and these effects were inhibited by the E antagonist, ICI 182,780 (19).”
BackgroundSelf-citation
Cited by
Changes in Proinflammatory Cytokine Activity after Menopause
Pfeilschifter, J., Köditz, R., Pfohl, M., & Schatz, H. (2002) · Endocrine Reviews · doi:10.1210/edrv.23.1.0456 · Cited by 914
Falahati-Nini, A., Riggs, B. L., Atkinson, E. J., O’Fallon, W. M., Eastell, R., & Khosla, S. (2000) · Journal of Clinical Investigation · doi:10.1172/jci10942 · Cited by 757
Self-citationVanderschueren, D., Vandenput, L., Boonen, S., Lindberg, M. K., Bouillon, R., & Ohlsson, C. (2004) · Endocrine Reviews · doi:10.1210/er.2003-0003 · Cited by 717
Osteoporosis Due to Cancer Treatment: Pathogenesis and Management
Pfeilschifter, J., & Diel, I. J. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.7.1570 · Cited by 363
Simvastatin Promotes Osteoblast Differentiation and Mineralization in MC3T3-E1 Cells
Maeda, T., Matsunuma, A., Kawane, T., & Horiuchi, N. (2001) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2000.4232 · Cited by 363
Metadata
- Authors
- Spelsberg, T. C.
- Venue
- Molecular Endocrinology
- Publisher
- The Endocrine Society
- Published
- 1999-06-01
- Volume
- 13
- Issue
- 6
- Pages
- 819-828
- ISSN
- 0888-8809 (ISSN-L)
- OpenAlex
- W1981874801
- Cited by
- 251
- References
- 3
- FWCI
- 4.68
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Actions and Interactions of Sex Steroids and Growth Factors/Cytokines on the Skeleton. https://app.cochat.ai/papers/10.1210/me.13.6.819
- The paper
- Spelsberg, T. C. (1999). The Actions and Interactions of Sex Steroids and Growth Factors/Cytokines on the Skeleton. Molecular Endocrinology. https://doi.org/10.1210/me.13.6.819
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.